125 avp  (Revvity)

Journal: Science Advances

Article Title: An AAV-CRISPR/Cas9 strategy for gene editing across divergent rodent species: Targeting neural oxytocin receptors as a proof of concept

doi: 10.1126/sciadv.adf4950

Figure Lengend Snippet: ( A ) Top images are representative I 125 -AVP autoradiograms of brain sections of AAV-CRISPR/Cas9–injected prairie voles, and bottom images are adjacent brain sections that show viral-induced eGFP fluorescence. Black arrows indicate the target area (VP, ventral pallidum). ( B ) Quantification of OXTR levels in AAV-ΔOXTR–injected hemispheres and AAV-CTRL–injected hemispheres. Paired t tests, ΔOXTR.1: N = 6, P = 0.37; ΔOXTR.2: N = 6, P = 0.38.

Article Snippet: Briefly, slides were thawed and fixed for 2 min in 0.1% paraformaldehyde in phosphate-buffered saline (PBS) for 2 min, washed in 50 mM tris in PBS (pH 7.4, 2 × 10 min), and incubated in 50 mM tris buffer, supplemented with 0.1% bovine serum albumin and 50 pM I 125 -OVTA (2200 Ci/mmol, ornithine vasotocin analog, #NEX254010UC, PerkinElmer, MA, USA) or 50 pM I 125 -AVP (2200 Ci/mmol, linear arginine vasopressin, #NEX310010UC, PerkinElmer) at room temperature (RT) for 1 hour.

Techniques: CRISPR, Injection, Fluorescence

Journal: Acta Pharmacologica Sinica

Article Title: β-Arrestin 2 mediates arginine vasopressin-induced IL-6 induction via the ERK 1/2 -NF-κB signal pathway in murine hearts

doi: 10.1038/s41401-019-0292-y

Figure Lengend Snippet: V 1A R mediates AVP-induced NF-κB activation and IL-6 induction in ARCFs and rat hearts. a The V 1A receptor subtype, but not the V 1B or the V 2 subtype, exists in ARCFs, as measured using RT-PCR. Total RNA was isolated from ARCFs and rat brains. RT-PCR was performed with primers designed to target each subtype of the AVP receptor. Similar results were reproduced at least three times. b – d The inhibition of the V 1A subtype by SR49059 abolished AVP-evoked NF-κB phosphorylation ( b ) and activation ( c ) and IL-6 mRNA production ( d ) in ARCFs. Starved cells were pretreated with 0.1 nM-1.0 μM SR49059 (a V 1A blocker) for 1 h and further stimulated with 1.0 μM AVP for 1 h ( b ), 24 h ( c ) and 12 h ( d ). The upper panel in b is a representative blot, and the lower panel shows the data expressed as the means ± SEM of three separate experiments. ** P < 0.01 vs. control, ## P < 0.01 vs. AVP alone. e – g SR49059 blocked the AVP-induced expression of IL-6 and NF-κB phosphorylation in rat hearts. After being pretreated with SR49059 (2.0 mg·kg −1 , ip) for 1 h, the animals were administered 0.5 U· kg −1 AVP via the tail vein for 6 h. The left ventricle was collected to measure NF-κB phosphorylation at 6 h after the administration of AVP. The data are expressed as the means ± SEM of four separate experiments. * P < 0.05 vs. vehicle, # P < 0.05, ## P < 0.01 vs. AVP alone. SR: SR49059

Article Snippet: The V 1A R selective antagonist SR49059 was purchased from Tocris Bioscience (Minneapolis, MN, USA).

Techniques: Activation Assay, Reverse Transcription Polymerase Chain Reaction, Isolation, Inhibition, Phospho-proteomics, Control, Expressing

Journal: British Journal of Pharmacology

Article Title: Body temperature and cardiac changes induced by peripherally administered oxytocin, vasopressin and the non-peptide oxytocin receptor agonist WAY 267,464: a biotelemetry study in rats

doi: 10.1111/bph.12613

Figure Lengend Snippet: The body temperature (°C) (A, C) and heart rate (beats min−1) (B, D) effects of the non-peptide V1A receptor antagonist SR49059 in combination with OT (A, B) and vehicle (C, D) over time (min). The vertical grey hashed line on the X-axis at 0 indicates the time of vehicle or SR49059 administration, while the second line at X = 15 indicates the time of vehicle or OT injection. Data are the means + SEM. VEH, vehicle; SR, SR49059.

Article Snippet: The V 1A receptor antagonist SR49059 ((S)-1-[(2R,3S)-5-chloro-3-(2-chloro-phenyl)-1-(3,4-dimethoxy-benzenesulfonyl)-3-hydroxy-2,3-dihydro-1H-indole-2-carbonyl]-pyrrolidine-2-carboxylic acid amide) was obtained from Axon Medchem BV (Groningen, The Netherlands).

Techniques: Injection

Journal: British Journal of Pharmacology

Article Title: Body temperature and cardiac changes induced by peripherally administered oxytocin, vasopressin and the non-peptide oxytocin receptor agonist WAY 267,464: a biotelemetry study in rats

doi: 10.1111/bph.12613

Figure Lengend Snippet: The effects of SR49059 on the body temperature (°C) (A) and heart rate (beats min−1) (B) changes induced by AVP over time (min). The vertical grey hashed line on the X-axis at 0 indicates the time of vehicle or SR49059 administration, while the second line at X = 15 indicates the time of vehicle or AVP injection. Data are the means + SEM. VEH, vehicle; SR, SR49059.

Article Snippet: The V 1A receptor antagonist SR49059 ((S)-1-[(2R,3S)-5-chloro-3-(2-chloro-phenyl)-1-(3,4-dimethoxy-benzenesulfonyl)-3-hydroxy-2,3-dihydro-1H-indole-2-carbonyl]-pyrrolidine-2-carboxylic acid amide) was obtained from Axon Medchem BV (Groningen, The Netherlands).

Techniques: Injection